FDA Places Clinical Hold On Neumora's Phase 1 Study Of NMRA-266; Stock Tanks In Pre-Market

(RTTNews) - Neumora Therapeutics, Inc. (NMRA) Monday said its Phase 1 study of NMRA-266 has been placed on clinical hold by the U.S. Food and Drug Administration (FDA). The decision was followed by recently available pre-clinical data showing convulsions in rabbits.

Subsequently, the company paused its Phase 1 study, in which about 30 participants were dosed with NMRA-266. No evidence of convulsions was observed in any participant.

The company's shares were down more than 14 percent in pre-market on Monday to $10.20. The stock had closed at $13.56, down 3.21 percent on Friday. It has been trading in the range of $9.35 - $21.00 in the last 1 year.